Pharma and healthcare: sector news on Monday 26 October 2026
Average tone +3.3 (positive) across 4 companies with relevant coverage, from 45 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +10.0 | 33 | Coverage was dominated by strong phase 3 data at ESMO, led by the experimental stomach cancer drug that doubled survival, alongside positive results for Tagrisso, Imfinzi and the Amgen combination. |
| GSK | +5.7 | 5 | Coverage focused on GSK's cancer pipeline, including strong response-rate data, its ovarian cancer drug at ESMO and a licensing deal with HUTCHMED. |
| Smith & Nephew | −1.2 | 4 | Coverage centres on merger talks with J&J collapsing over a CEO dispute, which weighs on sentiment. |
| Haleon | −1.2 | 3 | Coverage was divided between Zacks lowering Haleon to Strong Sell, having previously rated it Hold, and screening articles naming it among British AI-related healthcare shares worth watching. |
| Convatec | — | 0 |
Strongest stories in the sector
- +10.0 Late-stage trial showed survival twice as long.
- +10.0 Positive phase 3 survival result in gastric cancer
- +10.0 Doubled survival, big new franchise potential
- +10.0 ADC doubles overall survival in gastric cancer
- +10.0 Experimental drug doubled survival
- +10.0 Experimental drug doubled survival time
- +10.0 Trial shows stomach cancer treatment gave twice the survival.
- +10.0 Drug extends overall survival in late-stage trial
- +10.0 ADC improves survival in gastric cancer patients
- +10.0 Positive phase III gastric trial results
- +10.0 Imfinzi combination lowers the risk of dying from bladder cancer.
- +10.0 Drug clears survival bar in late-stage study
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.